In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.

The acquisition of Renaissance and its promising Phase III-ready asset for neuroblastoma could be the first of a number of deals in the near future, Essential CEO Emma Johnson tells Scrip.

The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.